Santen Pharmaceutical Co (4536.T) Stock Price
Santen Pharmaceutical Co Price
Santen Pharmaceutical Co (4536.T) Stock | ISIN JP3336000009 | WKN 864318. The current Santen Pharmaceutical Co stock price is 1,942 JPY (2026). Revenue is 293.38 B JPY. Net income is 38.54 B JPY. The P/E ratio is 17.62. Market capitalization is 679.11 B JPY. Santen Pharmaceutical Co operates in the Health sector.
Santen Pharmaceutical Co stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Santen Pharmaceutical Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Santen Pharmaceutical Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Santen Pharmaceutical Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Santen Pharmaceutical Co Price |
|---|
Santen Pharmaceutical Co Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Santen Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M JPY) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M JPY) |
| NET INCOME (M JPY) |
| NET INCOME GROWTH (%) |
| DIVIDEND (JPY)DIV. (JPY) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Santen Pharmaceutical Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Santen Pharmaceutical Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Santen Pharmaceutical Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Santen Pharmaceutical Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Santen Pharmaceutical Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Santen Pharmaceutical Co stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Santen Pharmaceutical Co Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Santen Pharmaceutical Co business model & stock analysis
Santen Pharmaceutical Co SWOT Analysis
Strengths
Santen Pharmaceutical Co Ltd boasts several strengths that contribute to its success and positioning in the market. Firstly, the company has a strong portfolio of innovative and high-quality pharmaceutical products across multiple therapeutic areas. This diverse range of offerings allows Santen to cater to a wide customer base and meet various medical needs.
Additionally, Santen has established itself as a leader in the ophthalmic industry. The company has a deep understanding of ocular health and has developed specialized expertise in this field. With this focus, Santen can provide targeted solutions for eye-related conditions, enabling it to gain a competitive edge.
Santen's commitment to research and development further strengthens its position. The company invests significant resources into innovation, continuously working to improve existing products and develop new treatments. This dedication to research enhances Santen's ability to stay ahead in the ever-evolving pharmaceutical industry.
Weaknesses
Despite its strengths, Santen Pharmaceutical Co Ltd faces certain weaknesses that can hinder its growth and performance. One notable weakness is its limited geographical presence. The company primarily operates within the Asian market, which limits its access to other potentially lucrative regions. Expanding into new markets could provide Santen with opportunities for further growth and revenue generation.
Furthermore, Santen's heavy reliance on a specific therapeutic area, namely ophthalmology, exposes it to potential risks. Any adverse developments in this field could significantly impact the company's financial performance. Diversifying its product offerings across various therapeutic areas could mitigate this vulnerability.
Opportunities
Santen Pharmaceutical Co Ltd operates in an industry with numerous opportunities for expansion and development. The growing global population, particularly in aging societies, presents a significant opportunity for the company. Age-related eye diseases, such as cataracts and glaucoma, are becoming more prevalent, creating a higher demand for ophthalmic treatments and medications. Santen can capitalize on this trend by developing innovative solutions tailored to address the specific needs of these patients.
Additionally, expanding into new markets, especially in regions with emerging economies, offers considerable growth potential. By establishing a presence in these markets, Santen can tap into a larger customer base and leverage increasing healthcare expenditure in these regions.
Threats
Santen Pharmaceutical Co Ltd faces certain threats that could impact its operations and market position. One significant threat is the intense competition within the pharmaceutical industry. Numerous companies are vying for market share, and Santen must continuously innovate and differentiate itself to retain its competitive advantage.
Furthermore, regulatory challenges and the need for stringent compliance pose potential threats. Adhering to various regulations and maintaining high safety standards across different markets can be complex and costly. Failure to comply could result in legal consequences and damage to the company's reputation.
Santen Pharmaceutical Co Eulerpool Fair Value
Santen Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio
Santen Pharmaceutical Co annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Santen Pharmaceutical Co shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Santen Pharmaceutical Co Dividend History
37 years of dividend payments · 2 consecutive increases
Santen Pharmaceutical Co dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Santen Pharmaceutical Co dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Santen Pharmaceutical Co Earnings Estimates
Santen Pharmaceutical Co Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/9/2024 | 7.73JPY | 77.67 BJPY | 2024 Q4 |
| 2/5/2024 | 13.42JPY | 73.33 BJPY | 2024 Q3 |
| 8/2/2023 | 22.22JPY | 71.56 BJPY | 2024 Q1 |
| 5/8/2023 | -73.16JPY | 77.11 BJPY | 2023 Q4 |
| 2/8/2023 | 103.73JPY | 70.84 BJPY | 2023 Q3 |
| 11/8/2022 | 9.76JPY | 64.14 BJPY | 2023 Q2 |
| 8/4/2022 | 16.69JPY | 64.5 BJPY | 2023 Q1 |
| 5/10/2022 | 19.81JPY | 69.73 BJPY | 2022 Q4 |
| 2/10/2022 | 14.9JPY | 67.46 BJPY | 2022 Q3 |
| 11/8/2021 | 16.05JPY | 62.17 BJPY | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Santen Pharmaceutical Co stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Santen Pharmaceutical Co shareholder structure
| % | Name |
|---|---|
6.97198% | |
5.47359% | |
3.9287% | |
3.04895% | |
2.88357% | |
2.81169% | |
2.31174% | |
2.0904% | |
2.01293% | |
1.9986% |
Santen Pharmaceutical Co Executives and Management Board
Mr. Akira Kurokawa
(71)Chairman of the Board · since 2006
Mr. Takeshi Ito
(64)President, Chief Executive Officer, Representative Director · since 2012
Mr. Kazuo Koshiji
Chief Financial Officer, Chief Risk Officer, Executive Officer
Mr. Rie Nakajima
(46)Chief Operating Officer, Executive Officer, Director · since 2023
Ms. Mika Masunari
Chief Compliance Officer, Executive Officer, General Counsel
Santen Pharmaceutical Co Supply Chain
Frequently asked questions about Santen Pharmaceutical Co
The business model of Santen Pharmaceutical Co Ltd revolves around developing and marketing innovative pharmaceutical products and medical devices for the field of ophthalmology. Santen focuses on providing solutions that address various eye diseases and conditions, including glaucoma, dry eye syndrome, and cataracts. By conducting extensive research and clinical trials, Santen aims to improve the quality of life for individuals suffering from ophthalmic disorders. Through strategic partnerships, targeted marketing, and continuous investment in research and development, Santen Pharmaceutical Co Ltd aims to position itself as a leading provider of ophthalmic treatments worldwide.
Santen Pharmaceutical Co stock
Santen Pharmaceutical Co Peer Group
Santen Pharmaceutical Co Ticker
Santen Pharmaceutical Co FIGI
All fundamentals and in-depth analysis of Santen Pharmaceutical Co
Our stock analysis for Santen Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Santen Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.